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The neuroprotective effect of recombinant human 
erythropoietin via an antiapoptotic mechanism on 
hypoxic-ischemic brain injury in neonatal rats 
Purpose: The neuroprotective effects of erythropoietin (EPO) have 
been recently shown in many animal models of brain injury, including 
hypoxic-ischemic (HI) encephalopathy, trauma, and excitotoxicity; 
however, limited data are available for such effects during the neonatal 
periods. Therefore, we investigated whether recombinant human 
EPO (rHuEPO) can protect against perinatal HI brain injury via an 
antiapoptotic mechanism. 
Methods: The left carotid artery was ligated in 7-day-old Sprague-
Dawley (SD) rat pups (in vivo model). The animals were divided into 
6 groups: normoxia control (NC), normoxia sham-operated (NS), 
hypoxia only (H), hypoxia+vehicle (HV), hypoxia+rHuEPO before a 
hypoxic insult (HE-B), and hypoxia+rHuEPO after a hypoxic insult 
(HE-A). Embryonic cortical neuronal cell culture of SD rats at 18 days 
gestation (in vitro model) was performed. The cultured cells were 
divided into 5 groups: normoxia (N), hypoxia (H), and 1, 10, and 100 
IU/mL rHuEPO-treated groups. 
Results: In the in vivo model, Bcl-2 expressions in the H and HV 
groups were lower than those in the NC and NS groups, whereas 
those in the HE-A and HE-B groups were greater than those of the H 
and HV groups. The expressions of Bax and caspase-3 and the ratio of 
Bax/Bcl-2 were in contrast to those of Bcl-2. In the in vitro model, the 
patterns of Bcl-2, Bax, and caspase-3 expression and Bax/Bcl-2 ratio 
were similar to the results obtained in the in vivo model.
Conclusion: rHuEPO exerts neuroprotective effect against perinatal HI 
brain injury via an antiapoptotic mechanism.
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Introduction
Erythropoietin (EPO), a hematopoietic cytokine known best 
for its erythropoietic effects, has neuroprotective effects in many 
animal models of brain injury, including hypoxic-ischemic (HI) 
encephlopathy, trauma and excitotoxicity
1). The biological effects 
of EPO in the central nervous system (CNS) are mediated by 
binding to its specific receptor (EPO-R). The expression of EPO 
and EPO-R in the nervous system is modulated by hypoxia and 
metabolic insult
2). EPO-R expression is abundant in the embryonic, 
fetal and adult brain of rats, mice, monkeys and humans
3, 4). EPO 
has been identified as a neurotrophic and neuroprotective agent in a 
wide variety of experimental paradigms, from neuronal cell culture 
to in vivo models of brain injury. Although the exact mechanisms 
of the neuroprotective action of EPO are not completely known, 
promotion of cell survival signaling cascades, modulation of 
intracellular calcium metabolism, attenuation of nitric oxide 
(NO) production, inhibition of glutamate release, anti-apoptosis, 
antioxidative and anti-inflammatory actions have been suggested as 
possible mechanisms
5).
EPO is known to promote cell survival via Bcl-2 family of 
genes in non-neuronal tissues and regulates the expression of 
apoptosis-related genes from Bcl-2 family in different experimental 
paradigms
6). EPO is able to shift the Bcl/Bax ratio towards a net 
antiapoptotic effect in cultured microglia
7). It also upregulates Bcl-
xl mRNA and protein expressions in cultured neurons
8). EPO 
reduced retinal ganglion cell death induced by glutamate and NO, 
and reversed Bcl-2 downregulation
9). EPO also increases Bcl-2 gene 
expression in rat cardiac myocytes after traumatic brain injury
10).
Various studies have demonstrated a protective effect of EPO 
in models of brain injury in vitro and in vivo
7, 10, 11). Here we 
investigated whether recombinant human EPO (rHuEPO) 
can protect the developing rat brain from HI injury via an anti-
apoptosis analyzing possible molecular mechanisms accounting for 
the neuroprotective effect of rHuEPO. 
Materials and methods
1. Materials
rHuEPO was purchased from CJ Cheiljedang Corporation 
(Seoul, Korea). Primary antibodies included the following: Bcl-
2 (1:1,000; Santa Cruz Biotechnology, Santa Cruz, CA, USA), 
Bax (1:1,000; Cell Signaling technolog, Danvers, MA, USA) 
and caspase-3 (1:1,000; Cell Signaling technology). Secondary 
antibodies used were goat anti-mouse or rabbit IgG-HRP (1:2000, 
Santa Cruz Biotechnology). 
2. Animal protocol and drug administration
The neonatal rat HI procedure was performed as described by 
Rice et al.
12). We chose 7-day-old Sprague-Dawley (SD) rat pups 
weighing between 12 and 16 g. The rat pups were anesthetized with 
ether. The left common carotid artery (CCA) was exposed, isolated 
and permanently doubly ligated with 5-0 surgical silk. The incision 
was sutured and the animal was allowed to recover in a warm 
environment. The whole surgical procedure was completed in less 
than 5 minutes. After a recovery period of 1 hour, the pups were 
placed in plastic chambers, which were submerged in a 37℃ water 
bath and exposed to hypoxia (mixture of 8% O2 and 92% N2) for 2 
hours. After this hypoxic exposure, the pups were returned to their 
dams for the indicated time. 
rHuEPO was prepared in phosphate-buffered saline (PBS) and 
injected intraperitoneally at a dose of 1,000 IU/kg 30 minutes 
before or after a hypoxic insult.
The animals were divided into six groups. In group 1 (Normoxia 
control, NC, n=7), they were not exposed to hypoxia. In group 2 
(Normoxia Sham-operated, NS, n=8), they were subjected only 
to open-close surgery without CCA ligation. In group 3 (Hypoxia 
only, H, n=8), they were subjected to hypoxia without rHuEPO 
injection. In group 4 (Hypoxia+vehicle, HV, n=7), they were 
injected with PBS (the same volume of rHuEPO). In group 5 
(Hypoxia+rHuEPO “before a hypoxic insult”, HE-B, n=8), they 
were injected with 1,000 IU/kg of rHuEPO 30 minutes before a 
hypoxic insult. In group 6 (Hypoxia+rHuEPO “after a hypoxic 
insult”, HE-A, n=8), they were injected with the same dose of 
rHuEPO 30 minutes after a hypoxic insult. Pups from each litter 
were randomly assigned and marked to the NC, NS, H, HV, HE-B 
or HE-A groups.
3. Hematoxylin and eosin (H & E) staining
Histologic studies were performed 7 days after a HI insult. After 
intracardiac perfusion with saline, the brains were removed, fixed 
in 4% paraformaldehyde, embedded in paraffin, and prepared for 
light microscopy. Four μm sections were mounted on glass cover 
slides. Sections were deparaffinized in xylene for 30 minutes and 
serially treated with 100% (5 minutes), 96% (10 minutes), and 
70% (10 minutes) ethanol. Slides were stained with hematoxylin, 
rinsed for a few seconds with water to remove excess stain, placed 
in 1% eosin, rinsed briefly in water to remove the acid and washed 
through the following series: 70%, 95% and 100% ethanol at 
5 minutes each. Finally, the slides were transferred to xylene for 
clearing, mounted, and covered with cover slips. 
Each slides were taken a photograph and were measured brain 
area with a densitometer (Multi-gauze software, Fuji Photofilm, 900      MS Kim, et al. • The neuroprotective effect of recombinant human erythropoietin in neonatal rats
Tokyo, Japan).
4. Cortical neuronal cell culture of rat embryos
The cortical neuronal cell culture of rat embryos based on the 
Brewer
13) method was performed. SD rats pregnant for 19 days were 
anesthetized with ether for 5 minutes at room temperature and the 
uteri were removed. The fetal pups were washed in 100% ethanol 
and Hanks’ balanced salt solution (HBSS) (GibcoBRL, Grand 
Island, NY, USA). The fetal pup brains were dissected at 37℃ 
HBSS containing 1 mM sodium pyruvate and 10 mM HEPES 
(pH 7.4). The dissected brain cortical tissues were then placed in 2 
mL trypsin and incubated at 37℃ water bath for 1 minute. Trypsin 
was removed by washing the tissues five times with 10 mL HBSS. 
The cells were moved in 1 mL HBSS, passed 6-7 times via pasteur 
pipette with tiny hole and dispersed. The cell suspension was 
centrifuged at 1,000 rpm at 25℃ for 5 minutes and pellets were 
washed with HBSS (without phenol red).
After cell counting, they were inoculated in plating Neurobasal 
media (GibcoBRL) (100 mL neurobasal, 2 mL B27 supplement, 
0.25 mL glutamax I, 0.1 mL 25 mM glutamate, 0.1 mL 25 mM 
2-mercaptoethanol) with about 2×10
6 cells/mm
2 in each dish. 
The cell cultures were incubated in a CO2 chamber. A fifth of the 
culture solutions were changed every three days and were replaced 
with feeding Neurobasal media (GibcoBRL).
The cultured cells were divided into five groups: normoxia 
group (N), hypoxia group (H) and hypoxia+1, 10 and 100 IU/
mL rHuEPO groups (H+E1, H+E10 and H+E100). The N group 
was prepared in 5% CO2 incubators while the H group and H+E 
groups in 1% O2 incubators (94% N2, 5% CO2) for 6 hours. The 
experiments were repeated four times (n=4).
5. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium 
bromide (MTT) assay
The MTT assay was used for estimation of cell viability and 
growth as originally described by Mosmann17). MTT was 
dissolved at a concentration of 5 mg/mL. Ten μL of the 5 mg/
mL MTT stock solution was added to each well. After 4 hour of 
incubation at 37℃, media was removed and added 100 μL of the 
lysing buffer (Dimethyl sulfoxide (DMSO) : 95% ethanol = 1 : 1). 
Absorbance of the samples was read at 492 nm using a microtiter 
plate enzyme-linked immunosorbent assay (ELISA) reader. The 
amount of formazan produced is proportional to the number of live 
and metabolically active cells.
6. Brain extraction and protein isolation
Pups were killed 7 days after a hypoxic insult. Left cerebral 
hemispheres from rat brains were immediately removed, frozen in 
liquid nitrogen and stored at -70℃ until use. Frozen tissues were 
homogenized in protein lysis buffer containing complete protease 
inhibitor cocktail tablets (Roche Applied Science, Mannheim, 
Germany), 1 M Tris-HCl (pH 8.0), 5 M NaCl, 10% Nonidet P-40 
and 1 M 1,4-dithio-DL-threitol (DTT). After incubation for 20 
minutes on ice, the samples were centrifuged at 12,000 rpm at 4℃
for 30 minutes and the supernatant was transferred to a new tube. 
Total protein was measured with a Bio-Rad Bradford kit (Bio-rad 
Laboratories, Hercules, CA, USA).
7. Western blotting
Samples of equal amounts of proteins (30 μg) were subjected to 
a 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
(SDS-PAGE) after denaturing in SDS gel-loading buffer (100 mM 
Tris-HCl (pH 6.8), 200 mM DTT, 20% glycerol, 4% SDS and 
0.2% bromophenol blue) in boiling water for 10 minutes. After 
electrophoresis proteins were electrotransferred onto polyvinylidene 
difluoride (PVDF) membrane (Millipore, Billerica, MA, USA) 
at a constant voltage of 10 V for 30 minutes. After transfer, the 
membrane was washed twice with 1 x tris-buffered saline (TBS) 
plus 0.1% Tween-20 (TBST pH 7.4) and then pre-incubated 
with a blocking buffer (5% nonfat dry milk in TBST) at room 
temperature for 1 hour. The membrane was then incubated 
with the primary antibodies 1:1,000 dilutions in TBST at 4℃ 
overnight. After washing, the blots were incubated with the 
secondary antibodies (1:2,000 dilution) at room temperature for 
1 hour. Finally, the membrane was washed and developed with 
an enhanced chemiluminoescence (ECL) Plus Western Blotting 
Detection System (Amersham Biosciences, Piscataway, NJ, USA) 
or SUPEX (Neuronex, Pohang, Korea).
8. Semiquantitation of the western blots
The intensity of the corresponding western blot band was 
measured by using a densitometer (Multi Gauge Software) and was 
calculated as the ratio of the signal intensity in the ischemic (left) 
hemisphere compared to the contralateral (right) hemisphere.
9. RNA extraction and real-time PCR 
Total RNA extraction was carried out with TRIzol reagent 
(Invitrogen Corporation, Carlsbad, CA, USA). Briefly, a piece of 
tissue was homogenized in 1 mL of TRIzol reagent. Total RNA was 
separated from DNA and proteins by adding chloroform and was 
precipitated using isopropanol. The precipitate was washed twice 
in 100% ethanol, air-dried and re-diluted in diethylpyrocarbonate 
(DEPC)-treated distilled water. The amount and purity of extracted Korean J Pediatr 2010;53(10):898-908 • DOI: 10.3345/kjp.2010.53.10.898    901
RNA was quantitated by GeneQuant 1,300 spectrophotometer 
(GE Healthcare, UK). The RNA was then stored at -70℃ before 
further processing. For real-time PCR (for reverse transcription), 
total RNA (1 μg) was reversely transcribed for 1 hour at 37℃ in 
a reaction mixture containing 20 U RNase inhibitor (Promega, 
Madison, WI), 1 mM dNTP (Promega, Madison, WI, USA), 
0.5 ng Oligo (dT) 15 primer (Promega, Madison, WI, USA), 1 
x RT buffer and 200 U M-MLV reverse transcriptase (Promega, 
Madison, WI, USA). The reaction mixture was then incubated at 
95℃ for 5 minutes to stop the reaction. The cDNA was then stored 
at -20℃ before further processing.
Real-time PCR was performed in 48 well PCR plates (Mini 
OpticonTM Real-Time PCR System) using the FINNZYMES 
DyNAmo SYBR green qPCR kit (Finnzymes, Beverly, MA, USA). 
Amplification conditions are shown in Table 1. The thermal profile 
was 95℃ for 15 minutes followed by 40 cycles of denaturation, 
annealing and extension as indicated in Table 1. Real-time PCR 
data were analysed with LightCycler software (Bio-rad Laboratories, 
Hercules, CA, USA). Each sample was conducted in triplicate.
10. Statistics analysis
Data were analyzed using the SPSS version 12 statistical analysis 
package (SPSS Inc., Chicago, IL, USA). Examined data were 
assessed using the t-test, GLM (general lineal model), and ANOVA. 
In each test, the data were expressed as the mean±SD, and P<0.05 
was accepted as statistically significant. 
Table 1. Primer Pairs and Annealing Temperature for Real-time 
Polymerase Chain Reaction
Name Primer Sequence (5’-3’) Annealing
Bcl-2
Bax
caspase-3
F:TTGACGCTCTCCACACACATG
R:GGTGGAGGAACTCTTCAGGGA
F:TGCTGATGGCAACTTCAACT
R:ATGATGGTTCTGATCAGCTCG
F:AATTCAAGGGACGGGTCATG
R:GCTTGTGCGCGTACAGTTTC
57℃
55℃
56℃
Fig. 1. Hematoxylin and eosin (H&E) staining after hypoxic insult of neonatal rat brain. 
A, Normoxia control group; B, Normoxia sham-operated group; C, Hypoxia group; D, 
Hypoxia+Vehicle group; E, Hypoxia+Recombinant human erythropoietin (rHuEPO)-
treated group before hypoxic insult; F, Hypoxia+rHuEPO-treated group after hypoxic 
insult. Comparison of the percentage of the area of the left hemisphere area with that 
of the right hemisphere: A, 102.8%; B, 94.8%; C, 58.5%; D, 68.6%; E, 94.3%; and F, 
81.4%.902      MS Kim, et al. • The neuroprotective effect of recombinant human erythropoietin in neonatal rats
Results
1. H & E staining after a hypoxic insult of neonatal rat brain
H & E stain of 7-day-old rat brain after a HI insult revealed that 
the brain areas in the H (C, 58.5%) and HV (D, 68.6%) groups 
were decreased compared to the NC (A, 102.8%) and NS (B, 
94.8%) groups, whereas those in the HE-B (E, 94.3%) and HE-A 
(F, 81.4%) groups were increased compared to the H (C, 58.5%) 
and HV (D, 68.6%) groups (Fig. 1). Percentages were the ratios of 
left hemisphere area compared to right hemisphere area.
2. The expressions of Bcl-2, Bax and caspase-3 proteins by 
western blot analysis in the neonatal HI brain injury
The expressions of Bcl-2 in the H and HV groups were decreased 
compared to the NC and NS groups, whereas those in the HE-A 
and HE-B groups were increased compared to the H and HV 
groups (P<0.05) (Fig. 2A). The expressions of Bax and caspase-3 
and the ratio of Bax/Bcl-2 in the H and HV groups were increased 
compared to the NC and NS groups, whereas those in the HE-A 
and HE-B groups were decreased compared to the H and HV 
groups (P<0.05) (Fig. 2B, 2C and 2D).  
3. The expressions of Bcl-2, Bax and caspase-3 mRNAs by 
real-time PCR on the HI brain injury in neonatal rats
The expressions of Bcl-2 in the H and HV groups were decreased 
compared to the NC and NS groups, whereas those in the HE-A 
and HE-B groups were increased compared to the H and HV 
groups (P<0.05) (Fig. 3A). The expressions of Bax and caspase-3 
and the ratio of Bax/Bcl-2 in the H and HV groups were increased 
compared to the NC and NS groups, whereas those in the HE-A 
and HE-B groups were decreased compared to the H and HV 
groups (P<0.05) (Fig. 3B, 3C and 3D).  
4. The images of cortical neuronal cell culture of rat 
embryos 
The cortical neuronal cells were observed using light microscopy 
Fig. 2. Western blots of Bcl-2 (A, NC, 100±0; NS, 104.8±1.0; H, 90.4±1.14; HV, 
87.9±0.56; HE-B, 112±1.12; HE-A, 102.8±0.37), Bax (B, NC, 100±0; NS, 100.3±0.73; 
H, 113.7±1.23; HV, 115.9±1.08; HE-B, 105.7±1.48; HE-A, 104.9±1.07), and caspase-3 
(C, NC, 100±0; NS, 100.9±0.41; H, 116.9±1.57; HV, 118.5±1.76; HE-B, 107.2±1.63; 
HE-A (105.9±2.51) antibodies 7 days after hypoxic insult, and the ratio of Bax/Bcl-
2 expression (D). Recombinant human erythropoietin (rHuEPO) was administered 
intraperitoneally at 1,000 IU/kg. NC, Normoxia control group (n=7); NS, Normoxia sham-
operated group (n=8); H, Hypoxia group (n=8); HV, Hypoxia+Vehicle group (n=7); HE-
B, Hypoxia+rHuEPO-treated group before hypoxic insult (n=8); HE-A, Hypoxia+rHuEPO-
treated group after hypoxic insult (n=8). *P<0.05 compared with hypoxia.
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under high magnification (×200). The cells in the N group (Fig. 
4A) appeared normal, whereas those in the H group (Fig. 4B) 
showed cellular damages. The cellular patterns of the H+E1 (Fig. 
4C) and H+E10 group (Fig. 4D) were similar to those in the N 
group, whereas the cells in the H+E100 group (Fig. 4E) appeared   
similar to those in the H group.
5. Cell viabilities of cultured cortical neuronal cells 
determined by the MTT assay
The relative cell viabilities in the H group were decreased 
compared to the N group. The relative cell viabilities in the H+E1 
and H+E10 group were similar to those in the N group, whereas 
those in the H+E100 group appeared similar to those in the H 
group (Fig. 5).
6. The expressions of Bcl-2, Bax and caspase-3 by proteins 
western blot analysis in the cortical neuronal cell 
culture
The expressions of Bcl-2 in the H group was decreased compared 
to the N group. whereas those in the H+E10 group were increased 
compared to the H group (P<0.05) (Fig. 6A). The expressions 
of Bax and the ratio of Bax/Bcl-2 in the H group were increased 
compared to the N group, whereas those in the H+E10 group were 
decreased gradually depending to the concentration of rHuEPO (P 
<0.05) (Fig. 6B and 6D). The expressions of caspase-3 the in the H 
group were increased compared to the N group, whereas those in 
the H+E1 and H+E10 groups were decreased compared to the H 
group (P<0.05) (Fig. 6C). 
7. The expressions of Bcl-2, Bax and caspase-3 mRNA by 
real-time PCR in cortical neuronal cell culture
The expressions of Bcl-2 in the H group were decreased compared 
to the N group. whereas those in the H+E1 group was increased 
compared to the H group (P<0.05) (Fig. 7A). The expressions of 
Bax and the ratio of Bax/Bcl-2 in the H group were increased 
compared to the N group, whereas those in the H+E1, H+E10 and 
H+E100 groups were decreased compared to the H group (P<0.05) 
(Fig. 7B and 7D). The expressions of caspase-3 in the H group were 
increased compared to the N group, whereas those in the H+E1 and 
H+E10 groups were decreased compared to the H group (P<0.05) 
(Fig. 7C). 
Fig. 3. Real-time PCR of Bcl-2 (A; NC, 100±0; NS, 91.4±2.63; H, 80.7±1.1; HV, 
77.4±1.39; HE-B, 118.1±1.63; HE-A, 115.7±2.32), Bax (B; NC, 100±0; NS, 100.7±0.51; 
H, 111.7±0.6; HV, 110.9±1.24; HE-B, 104.2±0.97; HE-A, 98.6±1.35), and caspase-3 (C; 
NC, 100±0; NS, 116.5±1.23; H, 135.7±2.8; HV, 139.5±1.11; HE-B, 97.3±0.68; HE-A, 
102.1±0.74) primers 7 days after hypoxic insult, and the ratio of Bax/Bcl-2 expression 
(D). Recombinant human erythropoietin (rHuEPO) was administered intraperitoneally at 
1,000 IU/kg. NC, Normoxia control group (n=7); NS, Normoxia sham-operated group 
(n=8); H, Hypoxia group (n=8); HV, Hypoxia+Vehicle group (n=7); HE-B, Hypoxia+ 
rHuEPO-treated group before hypoxic insult (n=8); HE-A, Hypoxia+rHuEPO-treated 
group after hypoxic insult (n=8). *P<0.05 compared with hypoxia.
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Discussion
HI brain injury in the human perinatal period can result 
from several pathological processes such as premature placental 
detachment or other complications of pregnancy and delivery. It is 
an important cause of neonatal mortality and subsequent sequelae 
such as cerebral palsy, mental retardation, learning disability and 
epilepsy
15). Hypoxia, ischemia, and more recently, intrauterine and 
neonatal infections, have been implicated in the pathogenesis of 
injury to the developing brain
15). Neonates who were exposed to HI 
brain injury sustain both acute and chronic morbidities that can 
affect the sensory, motor, cognitive and behavioral systems. The 
full extent of this injury may not be apparent until the child reaches 
school age or later
5). Premature neonates are particularly vulnerable 
to HI exposure and may develop a variety of deficits that will reveal 
themselves when tested at school entry
16).
A variety of therapeutic strategies are employed to protect against 
the pathologic mechanisms of HI injury. These include induction 
of hypothermia, antagonism of excitotoxic glutamate receptors, 
anti-inflammatory agents, neurotropic factors and inhibitors 
of the caspase pathway and of stress kinases
5). Pharmacological 
agents which mediate one or more of these processes may provide 
neuroprotection for patients against this condition. Furthermore, 
study of neuroprotective agents may provide important information 
about treatment for the perinatal HI brain injury. The in vivo 
neonatal rat HI model and the in vitro cortical cell culture model 
of rat embryos have been well characterized and used extensively to 
search for neuroprotective agents
17).  
Fig. 4. High-magnification (×200) photomicrograph of brain cortical cell culture from 
a 19-day-pregnant Sprague-Dawley rat. Recombinant human erythropoietin (rHuEPO) 
was administered at 1, 10, and 100 IU/mL. A, Normoxia group (N); B, Hypoxia group (H); 
C, Hypoxia+1 IU/mL rHuEPO-treated group (H+E1); D, Hypoxia+10 IU/mL rHuEPO-
treated group (H+E10); E, Hypoxia+100 IU/mL rHuEPO-treated group (H+E100). 
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Fig. 5. Cell viabilities were measured by the 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyl-tetrazolium bromide (MTT) assay. N (100±0), normoxia 
group; H (34.6±0.7), hypoxia group; H+E1 (84.6±1.72), hypoxia+1 
IU/mL recombinant human erythropoietin (rHuEPO)-treated group; 
H+E10 (61.5±1.14), hypoxia+10 IU/mL rHuEPO-treated group; H+E100 
(38.5±0.89), hypoxia+100 IU/mL rHuEPO-treated group. *P<0.05 
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EPO, a 34-kDa glycoprotein hormone, was first characterized 
as a hematopoietic growth factor. It is now widely used for 
the treatment of anemia associated with renal failure, cancer, 
prematurity, chronic inflammatory disease and human immuno-
deficiency virus infection. EPO is initially produced in the liver 
but shortly after birth, its production is shifted to the kidney
18). 
EPO has been originally characterized as the principal regulator 
of erythropoiesis by inhibiting apoptosis and by stimulating the 
proliferation and differentiation of erythroid precursor cells
19). EPO 
exerts remarkable neuroprotection in both cell cultures and in 
animal models of nervous system disorders and has been implicated 
in the development of the CNS. Neuroprotective effect of EPO 
has also been demonstrated on various animal models of cerebral 
ischemia
20). 
Recent studies have shown that EPO protects neonatal brains as 
well from HI injury by reducing apoptotic cell death in vivo
21) and 
protects cultured neurons against oxygen glucose deprivation injury 
by a paracrine protective pathway through astrocytes expressing 
EPO
22). EPO is also found to protect the developing rat brain 
against NMDA receptor antagonist neurotoxicity and protects 
the mouse retina against light-induced degeneration by inhibiting 
photoreceptor cell apoptosis
23). Our in vivo experimental study 
revealed that the brain areas in hypoxia were decreased compared 
to normoxia, whereas those in EPO-treated groups were increased 
compared to hypoxia.
In in vitro experiments, EPO has been shown to protect cultured 
hippocampal and cortical neurons against glutamate toxicity
24), 
hypoxia and glucose deprivation
25) and serum deprivation-
induced and kainic acid-induced apoptosis
24). In addition, systemic 
administrations of rHuEPO as a pretreatment or posttreatment 
have been shown to effectively reduce brain injury after focal 
ischemia
26), subarachnoid hemorrhage
27) and HI
28). Our in vitro 
experimental study showed the cells in normoxia appeared normal, 
whereas those in hypoxia showed cellular damages. And the cellular 
patterns in the low dose EPO-treated groups were similar to those 
in normoxia, whereas the cells in the high dose EPO-treated groups 
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Fig. 6. Western blots of Bcl-2 (A; N, 100±0; H, 97.6±0.96; H+E1, 95.2±0.45; H+E10, 
102.9±0.75; H+E100, 98.7±0.85), Bax (B; N, 100±0; H, 104.3±0.57; H+E1, 97.7±0.7; 
H+E10, 91±0.87; H+E100, 84.3±0.54), and caspase-3 (C, N, 100±0; H, 107.8±0.71; 
H+E1, 99.2±0.63; H+E10, 104.6±0.89; H+E100, 126.9±0.61) in cultured cortical 
neuronal cells from 19-day-old rat embryos, and the ratio of Bax/Bcl-2 expression 
(D). Recombinant human erythropoietin (rHuEPO) was administered at 1, 10, and 100 
IU/mL. A, Normoxia group (N, n=4); B, Hypoxia group (H, n=4); C, Hhypoxia+1 IU/
mL rHuEPO-treated group (H+E1, n=4); D, Hypoxia+10 IU/mL rHuEPO-treated group 
(H+E10, n=4); E, Hypoxia+100 IU/mL rHuEPO-treated group (H+E100, n=4). *P<0.05 
compared with hypoxia.
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appeared similar to those in hypoxia.
Both EPO and its specific receptor (erythropoietin receptor, 
EPO-R) are expressed in different tissues, including the nervous 
system
19). EPO acts via activation of the specific EPO-R. EPO 
and EPO-R are present in the developing human brain as early 
as 5 weeks post-conception, and each protein shows a specific 
distribution that changes with development
29). EPO-R have been 
identified in the nervous system of rodents, primates and humans
19, 
29) and have been localized on several primary cell lines of neurons, 
as well as in glial cells. It has been shown that EPO stimulates 
neurogenesis and prevents apoptosis in the embryonic brain
30). 
EPO-R is widespread throughout fetal brain
29). EPO-R binding 
initiates a signaling cascade that involves multiple antiapoptotic 
pathways that can account for the rHuEPO-induced reduction
26). 
EPO-R activation protects hippocampal neurons from ischemic 
neuronal damage through the inhibition of glutamate release via 
exocytosis in hippocampal slice cultures. In the brain, EPO is 
released by astrocytes
22), triggers dopamine release
31), promotes 
neurogenesis
32) and vasculogenesis
33), and stimulates proliferation 
of glia
34). EPO is therefore recognized to have both trophic and 
antiapoptotic mechanisms of action.
EPO might have a direct protective role against a variety of 
neurotoxic insults such as hypoxic conditions
24), glutamate toxi-
city
19), free-radical injury
35) and exposure to neurotoxicants
36). EPO 
stimulates dopamine release and tyrosine hydroxylase activity in 
PC12 cells, through the activation of calcium channels, induces 
membrane depolarization, stimulates mitogen activated protein 
kinase activity and increases NO synthesis
37). EPO reduces 
calcium-induced glutamate release from cultured cerebellar granule 
neurons
38). 
Apoptosis contributes significantly to cerebral damage during 
the perinatal period. In neonatal HI model, there is evidence that 
cerebral ischemia leads to delayed cell death with DNA damage
39). 
EPO has antiapoptotic action on some non-neural cells
40). There 
is some evidence suggesting that EPO may also protect neuronal 
cells that morphologically die via apoptosis both in vivo and 
in vitro. And EPO may also exert its neuroprotective effect via 
the differential regulating of gene expression ruling the balance 
between the expression of pro- and antiapoptotic molecules. 
EPO prevents ischemia-induced delayed neuronal death in the 
hippocampus in animal model of global cerebral ischemia
11). 
EPO decreases apoptotic cell death of neurons under conditions 
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Fig. 7. Real-time PCR of Bcl-2 (A; N, 100±0; H, 86.5±0.84; H+E1, 110.2±2.1; H+E10, 
76.8±1.38; H+E100, 91.4±0.98), Bax (B; N, 100±0; H, 123.9±1.31; H+E, 1,115.7±1.6; 
H+E10, 102.1±1.89; H+E100, 116.5±0.82), and caspase-3 (C; N, 100±0; H, 
135.7±0.79; H+E1, 126.6±1.16; H+E10, 88.9±0.69; H+E100, 134.7±0.74) mRNAs in 
cultured cortical neuronal cells from 19-day-old rat embryos, and the ratio of Bax/Bcl-
2 expression (D). Recombinant human erythropoietin (rHuEPO) was administered at 1, 
10, and 100 IU/mL. A, Normoxia group (N, n=4); B, Hypoxia group (H, n=4); C, Hypoxia 
+1 IU/mL rHuEPO-treated group (H+E1, n=4); D, Hypoxia+10 IU/mL rHuEPO-treated 
group (H+E10, n=4); E, Hypoxia+100 IU/mL rHuEPO-treated group (H+E100, n=4). *P 
<0.05 compared with hypoxia.
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of hypoxia in vitro, suggesting that it might have similar effect in 
vivo
29). Antiapoptotic action of EPO has also been confirmed in 
focal cerebral ischemia and transient spinal ischemia models
24). 
EPO decreases apoptotic cell death of neurons under conditions 
of hypoxia in vitro, suggesting that it might have a similar effect in 
vivo
29).
EPO inhibits caspase 8-, caspase 1- and caspase 3-like activities 
linked to cytochrome c release
35). EPO consistently increases the 
expression of the antiapoptotic gene Bcl-XL and decreases the 
expression of pro-apoptotic gene bak in PC12 cells. EPO is able to 
shift the Bcl/Bax ratio towards a net antiapoptotic effect in cultured 
microglia
7). It also up-regulates Bcl-XL mRNA and protein 
expressions in cultured neurons
8). EPO rescued hippocampal 
CA1 neurons from lethal ischemic damage and up-regulated the 
expressions of Bcl-XL mRNA and protein in the hippocampal 
CA1 field of ischemic gerbils. Thus, EPO prevents delayed neuronal 
death of hippocampal neurons, possibly through up-regulation of 
Bcl-XL, which is known to facilitate neuronal survival
8).
Western blot analysis and real-time PCR both our in vitro and in 
vivo models of perinatal HI brain injury revealed that the expres-
sions of Bcl-2 in hypoxia were decreased compared to in nomoxia 
whereas those in rHuEPO-treated groups were increased compared 
to  in hypoxia. The expressions of Bax after hypoxia as well as the 
ratio of Bax/Bcl-2 in hypoxia were increased compared to nomoxia 
whereas those in rHuEPO-treated groups decreased compared to 
hypoxia. In addition, the expressions of caspase-3 in hypoxia were 
increased compared to nomoxia whereas those in rHuEPO-treated 
groups were decreased compared to nomoxia. 
The above data suggest that rHuEPO’s nuroprotective effect 
against neonatal HI brain injury may have been via an anti-apop-
tosis mechanism which the ratio of Bax/Bcl-2 and the expressions 
of caspase-3 in rHuEPO-treated groups were increased compared 
to hpoxia.  
In conclusion, our experiments demonstrate that rHuEPO is 
able to prevent the degeneration of neonatal cerebral neuronal cells 
caused by a hypoxic insult. In addition, rHuEPO’s neuroprotective 
effects on HI brain injury in neonatal rats may be via anti-apoptosis. 
The present study may be useful for the further development of 
clinical therapies for perinatal HI encephalopathy-induced by 
cerebral hypoxia.
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